Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Radezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | CALML3 | P27482 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SDHA | P31040 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radezolid SCHEMBL1035776 | 0.99 | MAOA (0.56) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL3165892 | 0.99 | MAOA (0.56) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL30061945 | 0.99 | MAOA (0.56) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15633880 | 0.98 | MAOA (0.55) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15634852 | 0.96 | MAOA (0.53) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15634976 | 0.96 | MAOA (0.53) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15634749 | 0.95 | MAOA (0.52) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL12956217 | 0.93 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1036539 | 0.93 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1032249 | 0.93 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126991-B2 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2015-09-08 | — | — | US | claimed |
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2014-04-10 | — | — | US | claimed |
| EP-4184568-B1 | HIGH-FREQUENCY PACKAGE | NTT INC (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12489069-B2 | High frequency package | NTT, INC. (JP) | 2025-12-02 | — | — | US | disclosed |
| EP-4191659-B1 | PRODUCTION METHOD FOR HIGH-FREQUENCY PACKAGE | NTT INC (JP) | 2025-11-05 | — | — | EP | disclosed |
| EP-4191657-B1 | PACKAGE AND PRODUCTION METHOD THEREFOR | NTT INC (JP) | 2025-10-01 | — | — | EP | disclosed |
| US-12322668-B2 | Package and manufacturing method of the same | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2025-06-03 | — | — | US | disclosed |
| US-12272567-B2 | Manufacturing method for high-frequency package | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2025-04-08 | — | — | US | disclosed |
| US-20240421107-A1 | MOUNTING STRUCTURE | NTT, INC. (JP) | 2024-12-19 | — | — | US | disclosed |
| EP-4191659-A1 | PRODUCTION METHOD FOR HIGH-FREQUENCY PACKAGE | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-4191657-A1 | PACKAGE AND PRODUCTION METHOD THEREFOR | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-3970734-A2 | COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF | Global Bio Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022029838-A1 | PACKAGE AND PRODUCTION METHOD THEREFOR | 日本電信電話株式会社 | 2022-02-10 | — | — | WO | disclosed |
| WO-2022024289-A1 | PRODUCTION METHOD FOR HIGH-FREQUENCY PACKAGE | 日本電信電話株式会社 | 2022-02-03 | — | — | WO | disclosed |
| EP-2635307-B1 | PHARMACEUTICAL COMPOSITIONS | MELINTA SUBSIDIARY CORP (US) | 2020-07-29 | — | — | EP | disclosed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9126991-B2 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2635307-A2 | PHARMACEUTICAL COMPOSITIONS | Rib-X Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061360-A2 | PHARMACEUTICAL COMPOSITIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | RPL27A, GRHPR, RAD52 | MAOA 3452/4885CALML3 2920/4885MAOB 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.